Physician profile
Marc A Tecce
NPI 1871516096
$5,323.33
in general payments reported to CMS, 2019-2025
25 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,728 · 2020: $385 · 2021: $841 · 2022: $521 · 2023: $686 · 2024: $771 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $1,063.79 | 2021-2025 | Optimizer, Optimizer |
| Pfizer INC. | $980.58 | 2019-2025 | |
| Amgen INC. | $738.21 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $614.06 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $454.35 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $389.43 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $221.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.89 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $127.60 | 2019-2023 | Farxiga |
| Boston Scientific Corporation | $88.70 | 2022-2024 | Watchman Access System, Bodyguardian |
| Regeneron Healthcare Solutions, INC. | $70.94 | 2019 | |
| Astellas Pharma US INC | $57.84 | 2019-2020 | |
| Amarin Pharma, INC. | $56.95 | 2019 | |
| Esperion Therapeutics, INC. | $43.50 | 2022 | |
| Gilead Sciences, INC. | $38.37 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $38.22 | 2025 | |
| Merck Sharp & Dohme LLC | $31.88 | 2023 | Verquvo, Belsomra |
| Lexicon Pharmaceuticals, INC. | $28.09 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $23.12 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $20.71 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Agepha Pharma Fz LLC | $20.00 | 2024 | Lodoco |
| Inspire Medical Systems, INC. | $19.37 | 2023 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.86 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.89 | 2025 | Onpattro |
| Scpharmaceuticals INC. | $14.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Tecce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.